GlassScriptPhysician profile
Cara B Pendley
NPI 1376760439
$6,893.91
in general payments reported to CMS, 2019-2025
50 companies · $500 in 2025
The $500 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,551 · 2020: $1,633 · 2021: $582 · 2022: $662 · 2023: $475 · 2024: $491 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,466.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,399.55 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $673.47 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $448.18 | 2019-2021 | |
| Emd Serono, INC. | $428.29 | 2019-2023 | Mavenclad |
| Amgen INC. | $409.12 | 2019-2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $332.65 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $220.10 | 2019-2020 | |
| Biogen, INC. | $201.54 | 2019-2024 | Vumerity |
| Genentech USA, INC. | $197.05 | 2019-2020 | |
| Acorda Therapeutics, INC | $161.25 | 2019-2020 | |
| Akcea Therapeutics, INC. | $146.71 | 2019-2020 | |
| Genzyme Corporation | $140.02 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $139.41 | 2019 | |
| Sunovion Pharmaceuticals INC. | $123.08 | 2019-2020 | |
| Allergan, INC. | $121.66 | 2019-2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cara Pendley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.